Why the Biotron Limited share price cratered today

Biotron Limited (ASX:BIT) is working on a treatment that could help cure HIV patients.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the most popular speculative shares on the ASX over recent months in Biotron Limited (ASX: BIT) lost 22% or 4.5 cents to close at 16.5 cents in trade today even after the biotech presented some data from its Phase 2 clinical trial titled "Significant Immunological Outcomes after 12 weeks of BIT225 and Antiretroviral Therapy in an HIV-1 Phase 2 Clinical Trial".

In summary the healthcare researcher presented some of the trial results for its BIT225 drug to an HIV treatment research conference in Miami, Florida.

According to Biotron the data from the trial shows that "Bit225 is having a unique effect in patients, over and above viral suppression seen with current antiretroviral drugs…..The data shows that there are significant immunological benefits in patients receiving antiretroviral drugs with 200 mg BIT225 compared to antiretroviral drugs plus placebo".

This data sounds exciting, which makes the share price fall today curious, although it should be noted that the data was already public knowledge and in the market beforehand.

The data is also only from a Phase 2 trial, with biotechnology companies normally having to complete three different trial phases successfully before they can apply to a healthcare regulator such as the US Food and Drug Administration (FDA) to have their treatment or therapy approved for commercial sale.

A phase 2 trial is generally limited in its scope in terms of patient numbers, researchers involved, etc, to save on costs as clinical trials can be very expensive and often end in failure.

However, it now seems that Biotron Limited may be able to press ahead with a large scale Phase 3 trial for the BIT225 drug.

One major problem is funding, and Biotron is openly seeking a funding partner to "support future clinical trial evaluations to further characterise a clinical impact on viral eradication".

Unfortunately as at September 30, 2018 the company had just $896,000 cash in hand on its balance sheet, no revenues and a cash outflow of $606,000 for the quarter.

However on October 17 it reported it has raised $4.7 million via an options underwriting agreement with CPS Capital Group. It did concede though that it will still need a commercial partner to further fund more clinical trials.

The stock has risen from just 2 cents prior to the original September 28 announcement about the positive data from the Phase 2 trial.

Given its financial position and early stage status it looks a high-risk bet as biotech investing is speculative by nature. Others that have struggled to deliver positive returns for investors include Admedus Ltd (ASX: AHZ) and Mesoblast limited (ASX: MSB).

Motley Fool contributor Yulia Mosaleva has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Share Fallers

Why APA, Flight Centre, Harvey Norman, and Lynas shares are dropping today

These shares are ending the week in the red. But why?

Read more »

Paper aeroplane going down on a chart, symbolising a falling share price.
Travel Shares

Why did the Flight Centre share price just crash 17%?

Flight Centre shares are getting hammered on Friday. But why?

Read more »

Man with his head on his head with a red declining arrow and A worried man holds his head and look at his computer as the Megaport share price crashes today
Share Fallers

Why this ASX 300 stock is crashing 32% today

A brutal sell-off is underway after missing expectations.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why Appen, DUG, OFX, and WiseTech shares are tumbling today

Why are these shares being sold off today? Let's find out.

Read more »

A man with arms spread yells as he plunges into a swimming pool.
Share Fallers

BrainChip shares are tanking 11% as an industry titan is scorched

BrainChip's headache could be coming from 15,000 kilometres away.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Bapcor, Boss Energy, Challenger, and Rio Tinto shares are falling today

These shares are having a tough time on hump day. Why are investors hitting sell?

Read more »

Unsure man analysing data on laptop.
Share Fallers

2 ASX All Ords shares crashing over 13% on government warnings

These stocks are suffering from a government threat.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why A2 Milk, Cooper Energy, IDP Education, and Tyro shares are dropping today

These shares are missing out on the good times on Tuesday.

Read more »